Yen Slides as Japan Election Boosts Fiscal Stimulus Expectations 
Japanese Pharmaceutical Stocks Slide as TrumpRx.gov Launch Sparks Market Concerns 
Gold and Silver Prices Rebound After Volatile Week Triggered by Fed Nomination 
Japan Economy Poised for Q4 2025 Growth as Investment and Consumption Hold Firm 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
U.S.-India Trade Framework Signals Major Shift in Tariffs, Energy, and Supply Chains 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Vietnam’s Trade Surplus With US Jumps as Exports Surge and China Imports Hit Record 
Australian Household Spending Dips in December as RBA Tightens Policy 
Asian Markets Surge as Japan Election, Fed Rate Cut Bets, and Tech Rally Lift Global Sentiment 
U.S. Stock Futures Slide as Tech Rout Deepens on Amazon Capex Shock 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Johnson & Johnson is set to pay $230 million to settle a legal case over claims it encouraged and bolstered the opioid addiction predicament in the state of New York. Then again, it was mentioned that despite settling, the company did not acknowledge liability or any wrongdoing in what it was accused of.
What the J&J settlement means
As per BBC News, Johnson & Johnson settlement effectively prevented it from going to trial that is set to start on Tuesday, June 29. The hearing will present a number of opioid manufacturers and distributors as the defendants of the case.
The company said that its agreements with New York State are proportionate with the previous resolution to pay $5 billion to settle the opioid claims. It was added that the arrangement also requires Johnson & Johnson to discontinue the sale of painkillers across the country.
"The opioid epidemic has wreaked havoc on countless communities across New York state and the rest of the nation, leaving millions still addicted to dangerous and deadly opioids," Letitia James, the New York attorney general, said. "Johnson & Johnson helped fuel this fire, but today they're committing to leaving the opioid business - not only in New York but across the entire country."
J&J to take its problematic painkillers off the market
It was mentioned that addiction to opioids, both legal and illegal drugs, has become a serious issue, and this problem is ongoing in countries like the United States. In fact, based on the record of the Centers for Disease Control and Prevention, the country reported almost half a million deaths due to overdoses between the years 1999 and 2019.
While Johnson & Johnson is set to be removed from the trial in New York, it is still facing similar cases in other states such as California. At any rate, the deal with New York also asked the company to stop selling opioids, and it was learned that J&J already did so for some time now.
CNBC reported that Johnson & Johnson confirmed it has ended its opioid business a while ago, even before the settlement with New York. Since 2015, the company stopped marketing opioids in the U.S. and totally withdrew from the business in 2020.
